Clinical Trial Update: A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating peposertib (M3814) in combination with standard chemotherapy for ovarian cancer, with expansions in high-grade serous and low-grade ser…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Ovarian High-grade Serous Carcinoma
• Ovarian Low-grade Serous Carcinoma
• Peritoneal Cancer

Drugs mentioned

• Peposertib (M3814) (peposertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING